Hemolytic-uremic syndrome risk factors: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{HUS}}
{{HUS}}


es:
#HIV
{{CMG}}; {{AE}} {{AHS}}
{{CMG}}; {{AE}} {{AHS}}
==Overview==
==Overview==
The most potent risk factor in the development of Hemolytic Uremic Syndrome in childhood is infection with Verocytotoxin (shiga-like toxin)-producing bacteria, usually Enterohemorrhagic Escherichia coli (VTEC/STEC),and in some tropical regions Shigella dysenteriae type I . Other risk factors include genetic mutations in Complement factors, Pnemumococcal infections, Autoimmune diseases like SLE and Antiphospholipid Syndrome, Pregnancy, Antineoplastic and immunosupressive drugs, HIV infection and Organ transplantation.
The most potent risk factor in the development of Hemolytic Uremic Syndrome in childhood is infection with Verocytotoxin (shiga-like toxin)-producing bacteria, usually Enterohemorrhagic Escherichia coli (VTEC/STEC),and in some tropical regions Shigella dysenteriae type I . Other risk factors include genetic mutations in Complement factors, Pnemumococcal infections, Autoimmune diseases like SLE and Antiphospholipid Syndrome, Pregnancy, Antineoplastic and immunosupressive drugs, HIV infection and Organ transplantation.

Revision as of 17:31, 13 August 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome risk factors

CDC on Hemolytic-uremic syndrome risk factors

Hemolytic-uremic syndrome risk factors in the news

Blogs on Hemolytic-uremic syndrome risk factors

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]

Overview

The most potent risk factor in the development of Hemolytic Uremic Syndrome in childhood is infection with Verocytotoxin (shiga-like toxin)-producing bacteria, usually Enterohemorrhagic Escherichia coli (VTEC/STEC),and in some tropical regions Shigella dysenteriae type I . Other risk factors include genetic mutations in Complement factors, Pnemumococcal infections, Autoimmune diseases like SLE and Antiphospholipid Syndrome, Pregnancy, Antineoplastic and immunosupressive drugs, HIV infection and Organ transplantation.

Risk Factors

The most potent risk factor in the development of HUS is etiology advanced and Clinical associations . Other risk factors include [etiology unknown].

etiology advance

  • Infection induced
  1. Shiga and verocytotoxin (shiga-like toxin)-producing bacteria;enterohemorrhagic Escherichia coli, Shigella dysenteriaen type 1,Citrobacter
  2. Streptococcus pneumoniae, neuraminidase, and T-antigen exposure
  • Disorders of complement regulation
    • Complement factor H (CFH) mutation/ Factor H Defeciency (Autosomal Dominant)
    • Complement Factor I(CFI) Defeciency (Acquired antibody mediated)
    • Membrane co-factor protein Defeciency (MCP; CD46)
    • Factor B Overactivity (Complement Factor B mutation)
    • Diacylglycerol Kinase Epsilon gene mutations
  • von Willebrand proteinase, ADAMTS13 deficiency
  1. Genetic disorders of ADAMTS13
  2. Acquired von Willebrand proteinase deficiency; autoimmune, drug induced
  • Defective cobalamine metabolism.

Clinical associations with following diseases:

  1. Malignancy, cancer chemotherapy and ionizing radiation
  2. Calcineurin inhibitors and transplantation
  3. Pregnancy, HELLP syndrome and oral contraceptive pill
  4. Systemic lupus erythematosis and antiphospholipid antibody syndrome
  5. Glomerulopathy
  6. Familial, not included in part 1
  7. Unclassified

References

Template:WH Template:WS